bioAffinity (NASDAQ: BIAF) reported Q2 EPS of ($0.64), $1.46 better than the analyst estimate of ($2.10). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.7 million.

For earnings history and earnings-related data on bioAffinity (BIAF) click here.